Medication–induced movement disorders―therapy strategy with respect to Parkinson disease and Huntington's disease

Abstract

We reviewed medication–induced movement disorders (MIMD) with respect to common neurologic movement disorders. MIMD might require blockade of dopaminergic receptors and subsequent receptor supersensitivity. Parkinsonism, dyskinesia, akathisia, catalepsy/catatonia, neuroleptic malignant syndrome and hyperprolactinemia are all conditions that neurologists may encounter. Management requires cessation of antipsychotic medication, changing to brexpiprazole etc. that has less dopaminergic blockade, addition (for hypokinetic form) of possible levodopa, or addition (for hyperkinetic form) of valbenazine etc if necessary. Collaboration of neurologists and psychiatrists is recommended to maximize patients' quality of life.